Deficiency of human fumarylacetoacetase (FAH) activity results in hereditary tyrosinemia type I. Using the restriction enzymes BglII, KpnI and StuI and a 1.3-kb cDNA probe for the FAH gene, we have found 6 restriction fragment length polymorphisms (RFLPs). These RFLPs were utilised in 3 tyrosinemia families in which one or both parents are carriers of both a tyrosinemia and a pseudodeficiency gene for FAH. Full information was obtained in two of these families. The polymorphisms identified 6 haplotypes. The haplotype distribution was significantly different in 32 unrelated tyrosinemia patients compared with a reference population of 100 individuals. The combined polymorphism information content was 0.77.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00217128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis B.
Cell Mol Gastroenterol Hepatol
December 2024
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan. Electronic address:
Article Synopsis
- Researchers developed a new mouse model to study chronic hepatitis B (CHB) by delivering the HBV genome and a key enzyme, allowing for detailed immune profiling in a lab setting.
- The CHB mice showed ongoing HBV infection and had signs of exhausted immune cells, with treatments using IFNα and a TLR7 agonist leading to viral suppression and immune enhancement.
- This study's mouse model mimics immune exhaustion seen in CHB patients and suggests that targeted treatments could help restore immune function against HBV.
Mutation spectrum of Tyrosinemia type I in Iran, A retrospective cohort study.
Eur J Med Genet
October 2024
Shiraz Transplant Research Center (STRC), Shiraz University of Medical Sciences, Shiraz, Iran; Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Hereditary Tyrosinemia Type 1 (HT1) is a genetic disorder characterized by an autosomal recessive inheritance pattern, caused by mutations in the fumarylacetoacetate hydrolase (FAH) gene, which results in a deficiency of fumarylacetoacetase. In our study, we identified a total of 15 mutations, including 12 newly discovered and 3 previously reported pathogenic mutations, in a cohort of 19 Iranian patients with the acute form of HT1. Out of the 12 novel variants identified, 11 were missense variants: p.
View Article and Find Full Text PDFIn vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1.
Genetics
October 2024
Centre Hospitalier Universitaire de Québec Research Center and Faculty of Medicine, Laval University, Québec City, QC G1V 4G2, Canada.
Hereditary tyrosinemia type 1 is an autosomal recessive disorder caused by mutations (pathogenic variants) in fumarylacetoacetate hydrolase, an enzyme involved in tyrosine degradation. Its loss results in the accumulation of toxic metabolites that mainly affect the liver and kidneys and can lead to severe liver disease and liver cancer. Tyrosinemia type 1 has a global prevalence of approximately 1 in 100,000 births but can reach up to 1 in 1,500 births in some regions of Québec, Canada.
View Article and Find Full Text PDFModeling HBV Infection and Therapy in Immunodeficient NOD-Rag1-/-IL2RgammaC-null (NRG) Fumarylacetoacetate Hydrolase (FAH) Knockout Mice with Human Chimeric Liver.
Methods Mol Biol
July 2024
Division of Virology, Pathogenesis and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Chimeric mouse models with a humanized liver (Hu-HEP mice) provide a unique tool to study human hepatotropic virus diseases, including viral infection, viral pathogenesis, and anti-viral therapy. Here, we describe a detailed protocol for studying hepatitis B infection in NRG-derived fumarylacetoacetate hydrolase (FAH) knockout mice repopulated with human hepatocytes (FRG-Hu HEP mice). The procedures include (1) maintenance and genotyping of the FRG mice, (2) intrasplenic injection of primary human hepatocytes (PHH), (3) 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) drug reduction cycling to improve human hepatocyte repopulation, (4) human albumin detection, and (5) HBV infection and detection.
View Article and Find Full Text PDFEfficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases.
Cell Stem Cell
August 2024
Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. Electronic address:
Article Synopsis
- Cell-based ex vivo gene therapy for solid organs, especially the liver, faces technical difficulties, but researchers have developed a promising strategy for hepatocyte therapy.
- The team successfully expanded patient-derived hepatocytes and used a specific AAV variant with CRISPR-Cas9 technology to correct pathogenic mutations effectively.
- These edited hepatocytes were able to repopulate and mature in injured mouse livers, successfully treating tyrosinemia after transplantation, suggesting potential for treating liver diseases in humans.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!